Cherry Biotech is delighted to announce the entry into an agreement with Atelerix for the integration of the Atelerix cryogenic transport solution with Cherry Biotech’s OrganoidPlate.
This agreement will explore the integration of Atelerix’s patented hydrogel technology with Cherry Biotech’s advanced 3D organoid models to facilitate global extended-duration shipment. In collaboration, the companies aim to improve the reliability and consistency of transporting these temperature-sensitive materials without the complications of cold-chain logistics, enabling significant growth and expanded customer access to high-quality, human-relevant preclinical data worldwide.
“Partnering with Atelerix strengthens our ability to deliver cutting-edge organoid models to researchers in pharma and academia worldwide. In short, Aterelix is making easy global shipping for our product possible”, said Pierre Gaudriault, CBO of Cherry Biotech. “This latest partnership with Cherry Biotech is a key step in expanding our commercial traction, broadening market reach, and increasing visibility for Atelerix’s solutions. It is fantastic to work alongside such an innovative company”, said Alastair Carrington, CEO of Atelerix.
Read the full press release : Cherry Biotech x Atelerix Agreement_15122025
